Biomarker Tests for Molecularly Targeted Therapies — The Key to Unlocking Precision Medicine
Cet article présente les recommandations d'un comité d'experts américains sur l'usage de biomarqueurs dans les essais de thérapies ciblées
As the promise and the pitfalls of precision medicine gain increasing attention, enthusiasm about the field has been heightened by a rapid reduction in the cost of high-throughput genomic sequencing and a dramatic increase in the identification of potential molecular targets for therapy. Biomarker tests for molecularly targeted therapies can help physicians to select the most effective therapy for a patient’s condition and avoid treatments that could be ineffective or harmful. If precision medicine is to reach its potential, such biomarker tests will have to be developed in a timely fashion.
New England Journal of Medicine , article en libre accès, 2015